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Abstract
Cancers driven by oncogenic Ras proteins encompass some of the most deadly human cancer
types, and there is a pressing need to develop therapies for these diseases. While recent studies
suggest that mutant Ras proteins may yet be druggable, the most promising and advanced efforts
involve inhibitors of Ras effector signaling. Most efforts to target Ras signaling have been aimed
at the ERK mitogen-activated protein kinase and the phosphatidylinositol 3-kinase signaling
networks. However, to date, no inhibitors of these Ras effector pathways have been effective
against RAS mutant cancers. This ineffectiveness is due, in part, to the involvement of additional
effectors in Ras-dependent cancer growth, such as the Rac small GTPase and the p21-activated
serine-threonine kinases (PAK). PAK proteins are involved in many survival, cell motility, and
proliferative pathways in the cell and may present a viable new target in Ras-driven cancers. In
this review, we address the role and therapeutic potential of Rac and Group I PAK proteins in
driving mutant Ras cancers.
Background
The frequent mutational activation of Ras oncoproteins has stimulated considerable interest
in developing therapeutic approaches for blocking aberrant Ras signaling for cancer
treatment (1). Disappointingly, despite more than three decades of intensive effort by
researchers, no clinically effective anti-Ras drugs have been developed. However, with
cancer genome sequencing studies revealing that aberrant Ras signaling remains the most
significant driver of cancer growth, there is renewed interest in the search for the elusive
anti-Ras therapy (2). Currently, the most tractable approach to inhibit Ras is through
ablation of Ras effector signaling. However, given the complex nature of Ras signaling,
whether targeting one or multiple Ras effector signaling pathways will be required for
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effective and long-term therapy is unresolved (3). Currently, most efforts have centered on
the two canonical Ras effectors, the Raf serine/threonine protein kinases and the
phosphatidylinositol 3-kinases (PI3Ks) (4). Numerous inhibitors of each of these effector
pathways are currently under clinical evaluation. In this review, we focus on a lesser-studied
Ras effector pathway that leads to activation of the Rac small GTPase. Among the multitude
of Rac effectors, there is increasing evidence that the p21-activated serine/threonine kinases
(PAKs) may contribute significantly to cancer growth (5, 6). In this review we summarize
the evidence for aberrant Rac-PAK signaling in supporting RAS mutant cancer growth, and
the status of developing PAK inhibitors for cancer treatment.
Ras effector signaling
Ras proteins (H-Ras, N-Ras, K-Ras4A/B) function as GDP-GTP-regulated on-off switches,
cycling between active Ras-GTP-bound and inactive GDP-bound states (1). Guanine
nucleotide exchange factors promote the formation of active Ras-GTP, whereas GTPase
activating proteins (RasGAPs) stimulate GTP hydrolysis and formation of inactive Ras-GDP
(7, 8). Mutant Ras proteins contain single amino acid substitutions at G12, G13 or Q61,
making them refractory to RasGAP activity and persistently GTP-bound (1). KRAS
mutations comprise 86% of all RAS mutations, followed by NRAS (10%), with HRAS
mutation rarely seen in cancer (9).
Ras-GTP binds preferentially to a spectrum of functionally diverse downstream effectors
(3). Most attention has been focused on the Raf serine/threonine kinases, which activate the
ERK1/2 mitogen-activated protein kinases (Fig. 1). One Raf isoform, B-Raf, is mutated
frequently in human cancers (10). PI3Ks comprise the second most studied Ras effector
class. PI3K activation causes increased formation of phosphatidylinositol-3,4,5-
trisphosphate (PIP3) and activation of the AKT serine/threonine kinase. PI3K is mutated
frequently in cancer and PI3K is essential for RAS-driven cancer development (11, 12).
There are currently at least 30 inhibitors of the Raf-MEK-ERK pathway and 50 inhibitors of
the PI3K-AKT-mTOR pathway under clinical evaluation (clinicaltrials.gov(13)).
A less-studied Ras effector network results in activation of the Rac small GTPase. This can
be mediated through Ras interaction with an RBD-containing RacGEF, Tiam1 (14, 15) (Fig.
1). Another mechanism involves PI3K-mediated formation of PIP3, which then activates
Rac-selective GEFs (e.g., P-Rex, Vav) (16, 17).
The three Rac isoforms are members of the Rho branch of the Ras superfamily (18). They
are best known for their regulation of actin organization, in particular to regulate
lamellipodia induction and promotion of cell migration and pinocytosis. Rac also regulates
the formation of reactive oxygen species (19). The recent identification of activated Rac1
mutants in melanoma supports an important driver role for Rac in cancer growth (20), (21).
Like Ras, Rac is a GDP-GTP regulated binary switch, with Rac-GTP engaging multiple
effectors (22). While the precise effector(s) that drives Rac-dependent cancer growth
remains to be determined, the PAK protein kinases are intriguing candidates. Below, we
summarize the evidence for the importance of the Rac-PAK effector signaling pathway in
Ras-driven cancer development and growth.
Baker et al. Page 2






















Rac and Ras in cancer
Early studies identified upregulated Rac activation in H-Ras-transformed rodent fibroblasts
(15, 23, 24). These were followed by studies where dominant negative Rac1 mutants, which
sequester and inactivate RacGEFs, impaired the growth of H-Ras-transformed rodent
fibroblasts (25-27). Subsequent genetically-engineered mouse model studies found that
tissue-restricted genetic loss of Rac1 impaired mutant Kras-driven lung (28) and pancreatic
(29) cancer development. Furthermore, in a mutant Kras-driven model of papilloma
development, tumor tissue exhibited increased levels of Rac-GTP, and loss of one Rac1
copy alone was sufficient to reduce tumor growth and increase survival (30).
The key effectors that drive Rac-dependent cancer growth remain to be elucidated. In an
early study utilizing effector-binding mutants of Rac1 to study the effectors important for
transformation of NIH3T3 mouse fibroblasts, PAK1 was found to be dispensable (31).
These analyses suggested that Rac1 regulates at least four distinct effector-mediated
functions and that multiple pathways may contribute to Rac1-induced cellular
transformation. However, since subsequent studies identified cell type and species
differences in the effectors involved in Ras-mediated transformation (32, 33), a reevaluation
of the role of PAK1 in Rac-dependent cancer growth in human cancers is clearly merited.
Another Rac1 activity, upregulation of reactive oxygen species, in which PAK1 is also
involved (34), has been suggested to contribute to Rac1-mediated growth regulation
PAK activation in RAS mutant cancer
PAKs comprise a family of six proteins divided into two sub-groups: group I comprises
PAK1-3 and group II contains PAK4-6 (35). Since group I PAKs are Rac and Cdc42
effectors, whereas group II PAKs are Cdc42 only, we focus on the group I PAKs. Although
the group I PAKs share strong sequence identity in their kinase domains (92-95%), PAK1 is
thus far the most studied family member, so we focus primarily on PAK1 in this review.
Though PAK1 activity can be deregulated by a diversity of mechanisms in cancer that
include gene amplification and increased gene transcription (5, 36), here we focus on
activation of PAK downstream of Ras, RacGEFs, and Rac. While in the inactive
conformation within the cytosol, PAK1-3 form head-to-tail homodimers with the N-terminal
autoinhibitory domain (AID) of one monomer inserted within the C-terminal kinase domain
of another. Upon binding of Rac1-GTP to the GTPase binding domain (GBD) of group I
PAKs, a conformational change releases the AID from the kinase domain leading to
autophosphorylation at multiple serine/threonines and activation of PAK catalytic activity,
allowing phosphorylation of substrates (35). Additionally, plasma membrane-associated Rac
binding facilitates PAK plasma membrane recruitment, where PAKs can interact with
effectors.
PAK effector signaling in human cancer
Group I PAKs regulate a spectrum of catalytically diverse substrates (5, 6). The precise
substrates critical for PAK-dependent cancer growth remain to be fully understood and the
interplay of multiple substrates is likely involved. In particular, PAK1 facilitates cross-talk
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with both the Raf and PI3K effector signaling networks. PAK1 can enhance ERK signaling
by phosphorylation of Raf-1 (S338) and MEK1 (S298) (37-40). PAK1 also regulates the
PI3K-AKT-mTOR pathway, where PAK1 exhibits a kinase-independent scaffolding
function to facilitate PDK1-mediated recruitment of AKT to the plasma membrane to
facilitate AKT activation (41). The physiologic relevance of PAK1 cross-talk with ERK and
AKT signaling is supported by the observation that genetic or pharmacologic ablation of
PAK1 impaired both ERK and AKT activation in Kras-driven skin tumors (42).
Pharmacologic inhibitors of the Raf and PI3K pathways have been ineffective in RAS
mutant cancer cells, in part, due to kinome reprogramming mechanisms that stimulate
signaling activities that overcome inhibitor action (43-46). Consequently, combination
targeting of PAKs and members of these pathways, such as MEK, ERK, PI3K or AKT, may
help overcome these resistance mechanisms. However, PAK1 cross-talk with these Ras
effector pathways can be context-dependent as PAK1 suppression in KRAS mutant colon
carcinoma cells impaired anchorage-dependent and –independent proliferation, but not ERK
or AKT activation (47).
PAKs are also capable of influencing transcription of genes that promote cell cycle
progression and cell survival. In breast cancer and colon cancer cell lines, PAK1 can
phosphorylate β-catenin on S663 and S675, stabilizing β-catenin and promoting nuclear
translocation and transcriptional stimulation of TCF-responsive genes, including CCND1
and MYC (48, 49).
PAKs enhance cell survival by phosphorylating proteins associated with apoptosis. PAK1
phosphorylates Bad on S111 to prevent Bcl2 binding and induction of apoptosis (50).
Additionally, PAK1 can phosphorylate induce relocalization of Raf-1 to the mitochondria
where it also inhibits BAD by phosphorylating BAD on S112 (50).
PAKs are also critical mediators of the cytoskeleton and cell motility. PAK1 and PAK2
phosphorylate LIM-kinase on T508, which in turn phosphorylates cofilin to prevent actin
depolymerization (51, 52). Additionally, PAK1 can phosphorylate the p41-ARC subunit of
the Arp2/3 complex to promote actin nucleation and cell motility (53, 54). PAKs are also
involved in microtubule reorganization through both tubulin cofactor B (TCoB), a protein
responsible for assembling tubulin heterodimers (55), and through the inactivation of
stathmin, which is normally responsible for destabilizing microtubules at the leading edge of
cells (56-58).
Metabolism is a critically important factor to the survival of cancer cells because of their
high energy demands, and PAKs play a role in driving several metabolic processes that aid
tumor cell growth and survival. Increased macropinocytosis to facilitate increased
extracellular protein and lipid uptake is one consequence of the high metabolic requirements
of cancer cells (59). PAK1 was found to be necessary and sufficient for growth factor- and
Rac-induced macropinocytosis in NIH3T3 fibroblasts (60). Rac and PAK1 were found to be
both necessary for Bladder cancer cell macropinocytotic uptake of Bacille Calmette-Guerin,
a strain of bacteria used in the treatment of bladder carcinoma (61). Additionally, bacterial
uptake was also stimulated by activated K-Ras or H-Ras and this activity was blocked by
pharmacologic inhibition of group I PAKs (IPA-3). This study suggests that the activity
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state of PAKs in cancer cells could be a determinate for efficient uptake of cancer
therapeutics. Similarly, in pancreatic cancer cells, K-Ras-dependent stimulation of
macropinocytosis and uptake of albumen (62) may provide a basis for the efficacy of
albumen-bound (nab) paclitaxel for the treatment of this cancer. It will also be important to
assess a role for Rac-PAK signaling in K-Ras-dependent macropinocytosis to determine
whether pharmacologic inhibition of PAK1 may be an approach in blocking cancer cell
metabolism.
While PAKs are canonically thought of as functioning in the cytosol or at the plasma
membrane, they do contain several nuclear localization signals (NLS) and play several roles
within the nucleus. In zebrafish, PAK1 nuclear import is essential for development (63). In
cancer cells, increased nuclear accumulation of PAK1 has been associated with advanced
tumor stage in colorectal and breast tumors (64, 65). In breast tumors, increased nuclear
PAK1 is capable of phosphorylating ERα at S305 and causing it to become active in a
ligand-independent manner, leading to tamoxifen resistance (66). Finally, PAK1 can
translocate to the nucleus to drive transcription of fibronectin, which is crucial for
supporting pancreatic cancer cell growth and migration (67).
Role of PAK in RAS-driven cancer development and growth
The first evidence for a role for PAK1 in Ras-dependent growth transformation comes from
studies in model cell systems. Ectopic expression of a kinase-dead PAK1 dominant negative
mutant impaired H-Ras and Rac1 growth transformation of rat 3Y1 fibroblasts (68) or H-
Ras transformation of Rat-1 but not NIH3T3 mouse fibroblasts (69, 70). Similarly, dominant
negative Rac1 and kinase-dead PAK1 inhibited K-Ras transformation of MT4H1 rat
Schwann cells (71). Recently, using a mouse model of Kras-driven skin squamous cell
carcinoma formation, genetic ablation of Pak1 strongly impaired tumor initiation and
progression (42). Together, with the validated role of Rac1 in Ras-driven oncogenesis, these
observations implicate the Rac-PAK effector pathway as a target for the development of
anti-Ras therapeutic strategies. Like Ras, Rac is not considered a highly tractable drug
target. Therefore, below we focus on the development of PAK inhibitors for cancer
treatment.
Clinical-Translational Advances
PAK inhibitor development is still largely at the preclinical stage, with only one PAK
inhibitor evaluated in clinical trials (72). Due to the high sequence identity of the kinase
domains, most attempts thus far have yielded molecules with a high affinity for all group I
PAK members, and in some cases, inhibitory activity for both group I and II PAKs. Early
stage ATP-competitive PAK inhibitors (e.g., staurosporine, A-FL172) lacked selectivity for
PAK. The first PAK inhibitor to reach clinical trials was a pan-PAK inhibitor, PF-3758309
(73). This compound was identified originally as a hit in a screen for inhibitors of PAK4, but
it proved to effectively inhibit all PAK family members, in addition to other protein kinases.
Preclinical evaluation showed anti-tumor activity against multiple human tumor cell lines,
leading to Phase I evaluation in patients with solid tumors. Unfortunately, this trial was
stopped in phase I due to pharmacokinetic issues. More recently, derivatives of PF-3758309
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have been described with much improved pharmacologic properties, raising hope that this
class of compound may yet have clinical utility (74).
More recently, Licciulli et al. describe the discovery of a small-molecule
pyridopyrimidinone, FRAX597, that potently inhibits group I PAKs by preventing ATP-
binding and hydrolysis (75). FRAX597 exhibited high specificity and potency for Group I
PAKs, although potent inhibition of other kinases was also seen. When evaluated in vivo,
FRAX597 inhibited the tumorigenic growth of NF2-null Schwann cells. NF2 loss causes
Rac1 and PAK1 activation indicating that this compound could be viable therapeutic
strategy for treating PAK-dependent tumors. FRAX597 treatment also phenocopied genetic
loss of Pak1 and impaired Kras-driven skin tumorigenesis (42). Interestingly, in this mouse
model, both genetic and pharmacologic inhibition of PAK1 resulted in reduction of ERK
and AKT activity, supporting the importance of PAK1 signaling cross-talk with these two
Ras effector pathways.
Peterson and colleagues performed a screen to identify small molecule allosteric inhibitors
of Cdc42 activation of group I PAKs. The results of this screen led to the development of
IPA-3 (2,2′-dihydroxy-1,1′dinaphthyldsulfide), which interacts with the PBD/AID region of
group I PAKs and prevents their activation by GTPase binding (76, 77). IPA-3 showed
strong selectivity for group I PAKs, with no inhibitory activity for group II PAKs or more
than 200 other protein kinases evaluated. However, inability of IPA-3 to inhibit already
activated PAK1, the μM IC50 of this compound and it’s rapid metabolism to a toxic
compound, due to the reduction of the disulfide bond it contains, limit the ability to
transition IPA-3 as a clinically useful chemical platform.
Conclusions
With increasing experimental evidence validating a driver role PAKs in tumor growth and
invasion, a key issue for the clinical advancement of PAK inhibitors will be defining genetic
and/or biochemical markers that identify those cancers that will respond to anti-PAK
therapy. The position of PAK downstream of mutant K-Ras and Rac, in addition to PAK
signaling cross-talk with the key Ras effector pathways, support PAK inhibitors as a
therapeutic strategy for RAS mutant cancers. Given the involvement of multiple effectors in
driving RAS-dependent cancer growth, PAK inhibition in combination with inhibitors of Raf
or PI3K effector signaling will likely be required. Currently, pharmacologic inhibitors of
PAK1 also inhibit other Group I PAKs; whether PAK1-selective inhibitors are more
desirable and possible to develop are issues that remain to be resolved. Of the spectrum of
PAK substrates, which substrate(s) will provide a reliable biomarker for PAK inhibitor anti-
tumor activity also remains unclear. A survey of the patent literature indicates that more
PAK inhibitors are in the pipeline (78). As more potent and selective inhibitors become
available, the answers to many of these unresolved questions will likely be addressed.
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Ras effector signaling. The importance of the Raf-MEK-ERK and PI3K-AKT-mTOR
effector signaling networks are well validated drivers of mutant Ras-dependent cancer
growth. Rac is activated by Ras through direct (e.g., Tiam1) or indirect (via PIP3 formation)
activation of guanine nucleotide exchange factors for the Rac small GTPase. The group I
PAKs comprise one key effector family of Rac. Over 50 substrates of PAK1 have been
described (compiled from references 37 and 39). These substrates include components of the
ERK MAPK cascade. PAK1 can also function as a scaffold to facilitate AKT activation.
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